Impact of nonalcoholic fatty liver disease on the response to pegylated interferon-α therapy in patients with chronic hepatitis B
{{output}}
Hepatitis B surface antigen (HBsAg) clearance is regarded as the optimal therapeutic endpoint in patients with chronic hepatitis B (CHB). Pegylated interferon-α (PegIFNα) is currently one of the most effective strategies for achieving this goal. However, the... ...
